Upjohn Finance B.V., founded in 2019 and based in the Netherlands, serves as a financing arm for the global pharmaceutical company Pfizer Inc., which is headquartered in the United States. The company focuses on offering debt instruments to support its parent organization's strategic initiatives and operational needs.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| UPJOHN 1.36% 2027-06-23 EURUpjohn Finance B.V. | United States | 2027-06-23 | 1.362 | 2.60 |
| UPJOHN 1.91% 2032-06-23 EURUpjohn Finance B.V. | United States | 2032-06-23 | 1.908 | 3.74 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Since its inception, Upjohn Finance B.V. has actively engaged in the bond market, making its debut issuance in 2020. Notably, the company issued €1 billion in bonds that were well-received, reflecting a strong market presence. Currently, its bonds have yields that remain competitive within the pharmaceutical sector, appealing to retail investors seeking stable returns. Additionally, some recent issuances featured innovative structures tied to sustainability initiatives, signaling Upjohn’s commitment to responsible investing.